Some authors proposed that MRI accuracy was higher in HER2-positive and triple-negative breast cancer and less in luminal breast cancer (9, 19, 26), whereas others proposed that MRI accuracy significantly decreased in patients treated with HER2-targeted agents, resulting in an overestimation of the extent of the residual lesions due to the increase in neovascular permeability (27), which may lead to overtreatment in this subtype. Here, ERBB2 is linked to triple-negative breast carcinoma.